Roni Mamluk is the founder of Ayala Pharmaceuticals. Ayala Pharmaceuticals has raised $47M in total funding. Latest round: Series B. Based in Rehovot, Israel.
Roni Mamluk is the CEO of Ayala Pharmaceuticals, an Israeli clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics. The company specializes in cancer drugs, particularly those targeting Notch activating mutations in solid tumors and blood cancers. Ayala Pharmaceuticals secured a $17 million Series A round and a $30 million Series B round, the latter led by Novartis.
Full founder directory · Investor directory · Company funding database · Fundraising library